Public Sector Pension Investment Board Buys 36,460 Shares of Tandem Diabetes Care, Inc. $TNDM

Public Sector Pension Investment Board increased its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 16.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 263,564 shares of the medical device company’s stock after buying an additional 36,460 shares during the period. Public Sector Pension Investment Board’s holdings in Tandem Diabetes Care were worth $3,200,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. CWM LLC grew its stake in Tandem Diabetes Care by 262.6% in the 2nd quarter. CWM LLC now owns 2,796 shares of the medical device company’s stock worth $52,000 after acquiring an additional 2,025 shares in the last quarter. CoreCap Advisors LLC boosted its holdings in shares of Tandem Diabetes Care by 270.3% in the third quarter. CoreCap Advisors LLC now owns 4,751 shares of the medical device company’s stock valued at $58,000 after purchasing an additional 3,468 shares during the period. Nisa Investment Advisors LLC grew its stake in Tandem Diabetes Care by 186.9% in the second quarter. Nisa Investment Advisors LLC now owns 4,171 shares of the medical device company’s stock worth $78,000 after purchasing an additional 2,717 shares in the last quarter. 180 Wealth Advisors LLC purchased a new position in Tandem Diabetes Care during the 3rd quarter worth $126,000. Finally, Praxis Investment Management Inc. bought a new stake in Tandem Diabetes Care during the 3rd quarter valued at $150,000.

Tandem Diabetes Care Stock Performance

Shares of Tandem Diabetes Care stock opened at $24.57 on Friday. The company has a market capitalization of $1.67 billion, a PE ratio of -8.00 and a beta of 1.68. The company has a 50-day simple moving average of $20.91 and a two-hundred day simple moving average of $17.02. Tandem Diabetes Care, Inc. has a one year low of $9.98 and a one year high of $35.12. The company has a debt-to-equity ratio of 2.33, a quick ratio of 1.90 and a current ratio of 2.44.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Thursday, February 19th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.04. The firm had revenue of $290.38 million for the quarter, compared to the consensus estimate of $277.14 million. Tandem Diabetes Care had a negative net margin of 20.17% and a negative return on equity of 70.01%. The company’s quarterly revenue was up 15.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.01 EPS. Research analysts expect that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on TNDM shares. Canaccord Genuity Group set a $35.00 target price on Tandem Diabetes Care and gave the stock a “buy” rating in a report on Wednesday, December 17th. Truist Financial set a $24.00 price objective on shares of Tandem Diabetes Care and gave the stock a “hold” rating in a research note on Thursday, December 18th. Wall Street Zen raised shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. UBS Group reaffirmed a “neutral” rating and issued a $22.00 price target (up previously from $17.00) on shares of Tandem Diabetes Care in a research report on Friday. Finally, Barclays increased their price objective on shares of Tandem Diabetes Care from $51.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, November 10th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $25.50.

More Tandem Diabetes Care News

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Q4 beat on top- and bottom-line metrics — revenue of $290.4M (vs. consensus ~$277M), EPS loss narrower than expected and record quarterly sales and pump shipments; management highlighted margin expansion. Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance
• Positive Sentiment: Market reaction: shares surged intraday after the results and outlook, reflecting investor enthusiasm for the beat, margin momentum and sales growth. Tandem Diabetes Shares Rise 33% On Earnings Beat, Margin Expansion, Growth Outlook
• Positive Sentiment: Analyst upgrades/raise: BofA moved TNDM from Underperform to Neutral and raised its target to $30, and several analysts raised forecasts or price targets after the upbeat quarter. These upgrades support further upside momentum. B of A Securities upgrades Tandem Diabetes Care (TNDM)
• Neutral Sentiment: FY‑2026 revenue guidance (~$1.1B) was reiterated/issued and generally in line with consensus — provides visibility but isn’t a clear upside surprise. Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance
• Neutral Sentiment: New pay-as-you-go (subscription) model announced — could expand long-term addressable market and recurring revenue but timing and transition impact are unclear. Tandem stock rises on Q4 beats, new pay-as-you-go model
• Negative Sentiment: Analyst caution: UBS and other analysts maintained Hold ratings, flagging pay‑go transition uncertainty and competitive headwinds that could limit near-term upside — supporting more conservative views. Tandem Diabetes Care: Solid Q4 Beat Offset by PayGo Transition Uncertainty and Competitive Headwinds Supporting Hold Rating
• Negative Sentiment: Mixed price-target moves: some firms raised targets but others (e.g., Stifel’s $22 target) still imply limited near-term upside versus the current price, underscoring divergent analyst views. Tandem Diabetes price target raised by Stifel

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.